Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

Healthcare Biotechnology
RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Replicel Life Sciences Inc
Bullboard Posts
User Avatar Image
(3)
•••
Comment by lv_426on Feb 04, 2020 11:02am
55 Views
Post# 30639726

RE:RE:RE:RE:RE:RE:RE:RE:New update today

RE:RE:RE:RE:RE:RE:RE:RE:New update today
bluemoons20 wrote: I apreciate the regulars being keen for this to go  but it would seem to be a large dose of wishful thinking.

I have been in this  for about 3 years st 4 times the current price.As has been said before,  in these markets  someone always knows something and the market usually responds well before the actual announcement.

This will not really be anything until the CE mark is achieved,  however, a bit disappointing that on this news there is not a jump to  .45 or .55  range  but actually goes down  on little volume.

I hope things work out  but  hopes not too high.


Been here for about the same time. Three years ago this news would have moved the price.....market is well aware of Lee now. You are also right about someone knowing before hand....usually see some movement before good/bad news
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities